A Randomized Phase Iii Study Of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax And Obinutuzumab In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (Cll)

The primary objective of this study is to compare the progression-free survival (PFS) between control treatment and experimental treatment strategies: ibrutinib/obinutuzumab (IO) with ibrutinib maintenance (IM) versus ibrutinib/venetoclax/obinutuzumab (IVO) regardless of IM or observation.